Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid LeukemiaHemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm, therapy related acute myeloid leukemia and myelodysplastic syndromeActive, not recruitingPhase 22026-06-12NCT04214249

1 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
National Cancer Institute (NCI)3015

10 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Dartmouth Hitchcock Medical Center/Dartmouth Cancer CenterLebanonUnited States200
Mayo Clinic in FloridaJacksonvilleUnited States224
Northwestern UniversityChicagoUnited States727
UC Irvine Health/Chao Family Comprehensive Cancer CenterOrangeUnited States189
University of Alabama at Birmingham Cancer CenterBirminghamUnited States186
VCU Massey Comprehensive Cancer CenterRichmondUnited States273
Wake Forest Baptist Health - Wilkes Medical CenterWilkesboroUnited States27
Wake Forest University at ClemmonsClemmonsUnited States48
Wake Forest University Health SciencesWinston-SalemUnited States330
Yale UniversityNew HavenUnited States352